Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer.

Trial Profile

Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Estradiol (Primary) ; Estradiol congeners; LHRH receptor modulators
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PATCH
  • Most Recent Events

    • 26 Oct 2016 Planned End Date changed from 31 Mar 2018 to 1 Aug 2021.
    • 16 Dec 2015 Accrual to date is 43% according to United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 42% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top